Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update ...
Key opportunities in the iPSC market include focusing on fibroblasts and hepatocytes for cell type growth, expanding drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback